Expand all sections

Mosunetuzumab

Extended indication Refractory follicular lymphoma (FL)
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Mosunetuzumab
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication Indolent non-Hodgkin’s lymphoma
Extended indication Refractory follicular lymphoma (FL)
Manufacturer Genentech
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulant.

Registration

Registration route Centralised (EMA)
Type of trajectory Accelerated assessment
Submission date November 2021
Expected Registration July 2022
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet
Frequency of administration 1 times every 4 weeks
References NCT04712097
Additional remarks Patients will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.